Monday, July 15, 2024

Cell Therapy Collaboration: IASO Bio and Innovent Strengthen Alliance with FUCASO® Deal

Similar articles

IASO Biotechnology and Innovent Biologics announced a significant enhancement of their strategic collaboration in the field of cell therapy. This collaboration includes IASO Bio’s acquisition of Innovent’s rights to FUCASO® (Equecabtagene Autoleucel), a groundbreaking BCMA CAR-T cell therapy, along with Innovent’s equity investment in IASO Bio.

According to the agreement, IASO Bio will purchase Innovent’s relevant rights to FUCASO® under the original “BCMA CAR-T Cell Therapy Cooperation Agreement” at an agreed price. Innovent will use the proceeds to acquire an 18% stake in IASO Bio. This new strategic cooperation framework allows IASO Bio to obtain global commercial rights and the intellectual property license for FUCASO®. IASO Bio will be fully responsible for the development, manufacturing, and commercialization of the product, while Innovent becomes a strategic shareholder of IASO Bio.

FUCASO® was jointly developed by IASO Bio and Innovent and was approved by the National Medical Products Administration (NMPA) on June 30, 2023, to treat relapsed and/or refractory multiple myeloma (RRMM) patients who have undergone at least three lines of prior treatment. FUCASO® is the world’s first approved fully human CAR-T product and the first approved BCMA CAR-T product in China. On March 28, 2024, FUCASO® received the investigational new drug (IND) application for treating RRMM patients who have undergone one to two lines of prior therapies and are refractory to lenalidomide. Additionally, its IND application for the treatment of autoimmune diseases such as refractory generalized myasthenia gravis (gMG) has been approved in both China and the United States.

Cell Therapy Leaders Celebrate Strengthened IASO Bio and Innovent Partnership

Ms. Zhang Jinhua, Founder, Chairwoman, and CEO of IASO Bio, expressed gratitude towards Innovent for their trust in IASO Bio’s research, development, and commercialization capabilities. She highlighted the strong partnership built over six years and the mutual innovation and growth witnessed in the biopharmaceutical field. She believes that the new strategic alliance will bring significant synergistic effects, leveraging both parties’ strengths to advance innovative therapeutic solutions and achieve mutual success.

Dr. Michael Yu, Founder, Chairman, and CEO of Innovent, acknowledged IASO Bio’s expertise, innovation, and strong execution capabilities in cell therapy. He emphasized that the new collaboration model would leverage mutual strengths and resources more effectively, providing integrated resources and dedicated teams for the manufacturing, development, and commercialization of CAR-T cell therapy. He affirmed Innovent’s continued support for IASO Bio as a strategic shareholder, looking forward to improving medication accessibility and bringing hope to patients worldwide.

Cell Therapy

Innovent’s Strategic Moves Boost Cell Therapy Advancements with IASO Bio Collaboration

Innovent has launched ten products in the market, with four new drug applications under regulatory review, four assets in Phase III or pivotal clinical trials, and eighteen more molecules in early clinical stages. Innovent partners with over thirty global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem, and MD Anderson Cancer Center. Guided by the motto “Start with Integrity, Succeed through Action,” Innovent maintains the highest standards of industry practices and collaborates to advance the biopharmaceutical industry, making first-rate pharmaceutical drugs widely accessible.

This strategic collaboration marks a significant step in advancing cell therapy treatments for cancer and autoimmune diseases. By integrating resources and expertise, IASO Bio and Innovent aim to accelerate the development and commercialization of innovative therapies, potentially benefiting millions of patients worldwide. The acquisition of global commercial rights and intellectual property licenses for FUCASO® positions IASO Bio to lead in the cell therapy market, while Innovent’s equity investment solidifies its commitment to supporting groundbreaking biopharmaceutical innovations.

With this strengthened partnership, both companies are poised to make substantial advancements in the field of cellular immunotherapy. IASO Bio’s responsibility for the development, manufacturing, and commercialization of FUCASO® will likely drive significant progress in treatment options for relapsed and refractory multiple myeloma, as well as other indications like generalized myasthenia gravis. Innovent’s strategic investment and continued collaboration will enhance the capabilities of both companies, fostering an environment of innovation and excellence in biopharmaceutical development.

You can follow our news on our Telegram and LinkedIn accounts.


Resource: Innovent Biologics, July 05, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article